640 related articles for article (PubMed ID: 30569382)
1. Neurological update: MOG antibody disease.
Wynford-Thomas R; Jacob A; Tomassini V
J Neurol; 2019 May; 266(5):1280-1286. PubMed ID: 30569382
[TBL] [Abstract][Full Text] [Related]
2. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.
Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Ringelstein M; Trebst C; Winkelmann A; Schwarz A; Buttmann M; Zimmermann H; Kuchling J; Franciotta D; Capobianco M; Siebert E; Lukas C; Korporal-Kuhnke M; Haas J; Fechner K; Brandt AU; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B;
J Neuroinflammation; 2016 Sep; 13(1):280. PubMed ID: 27793206
[TBL] [Abstract][Full Text] [Related]
3. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome.
Jarius S; Kleiter I; Ruprecht K; Asgari N; Pitarokoili K; Borisow N; Hümmert MW; Trebst C; Pache F; Winkelmann A; Beume LA; Ringelstein M; Stich O; Aktas O; Korporal-Kuhnke M; Schwarz A; Lukas C; Haas J; Fechner K; Buttmann M; Bellmann-Strobl J; Zimmermann H; Brandt AU; Franciotta D; Schanda K; Paul F; Reindl M; Wildemann B;
J Neuroinflammation; 2016 Nov; 13(1):281. PubMed ID: 27802825
[TBL] [Abstract][Full Text] [Related]
4. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M;
J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675
[TBL] [Abstract][Full Text] [Related]
5. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Current Insights into the Disease Pathophysiology, Diagnosis and Management.
Ambrosius W; Michalak S; Kozubski W; Kalinowska A
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33374173
[TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics of myelin oligodendrocyte glycoprotein antibody neuromyelitis optica spectrum disorder.
Salama S; Pardo S; Levy M
Mult Scler Relat Disord; 2019 May; 30():231-235. PubMed ID: 30825703
[TBL] [Abstract][Full Text] [Related]
7. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
[TBL] [Abstract][Full Text] [Related]
8. [Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis: Diagnosis and Treatment].
Wildemann B; Horstmann S; Korporal-Kuhnke M; Viehöver A; Jarius S
Klin Monbl Augenheilkd; 2020 Nov; 237(11):1290-1305. PubMed ID: 33202462
[TBL] [Abstract][Full Text] [Related]
9. Increased interleukin-6 correlates with myelin oligodendrocyte glycoprotein antibodies in pediatric monophasic demyelinating diseases and multiple sclerosis.
Horellou P; Wang M; Keo V; Chrétien P; Serguera C; Waters P; Deiva K
J Neuroimmunol; 2015 Dec; 289():1-7. PubMed ID: 26616865
[TBL] [Abstract][Full Text] [Related]
10. [Optic neuropathy in positive anti-MOG antibody syndrome].
Merabtene L; Vignal Clermont C; Deschamps R
J Fr Ophtalmol; 2019 Dec; 42(10):1100-1110. PubMed ID: 31732265
[TBL] [Abstract][Full Text] [Related]
11. Clinical profile, imaging features and short term visual outcomes of Indian optic neuritis patients with and without seromarkers for myelin oligodendrocyte glycoprotein and neuromyelitis optica.
Ambika S; Durgapriyadarshini S; Padmalakshmi K; Noronha V; Arjundas D
Indian J Ophthalmol; 2022 Jan; 70(1):194-200. PubMed ID: 34937238
[TBL] [Abstract][Full Text] [Related]
12. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype.
Kitley J; Woodhall M; Waters P; Leite MI; Devenney E; Craig J; Palace J; Vincent A
Neurology; 2012 Sep; 79(12):1273-7. PubMed ID: 22914827
[TBL] [Abstract][Full Text] [Related]
13. Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands.
van Pelt ED; Wong YY; Ketelslegers IA; Hamann D; Hintzen RQ
Eur J Neurol; 2016 Mar; 23(3):580-7. PubMed ID: 26593750
[TBL] [Abstract][Full Text] [Related]
14. Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated CNS Demyelination: Clinical Spectrum and Comparison with Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder.
Ojha PT; Aglave VB; Soni G; Jagiasi KA; Singh RK; Singh RK; Nagendra S
Neurol India; 2020; 68(5):1106-1114. PubMed ID: 33109860
[TBL] [Abstract][Full Text] [Related]
15. Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease.
Höftberger R; Sepulveda M; Armangue T; Blanco Y; Rostásy K; Calvo AC; Olascoaga J; Ramió-Torrentà L; Reindl M; Benito-León J; Casanova B; Arrambide G; Sabater L; Graus F; Dalmau J; Saiz A
Mult Scler; 2015 Jun; 21(7):866-874. PubMed ID: 25344373
[TBL] [Abstract][Full Text] [Related]
16. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
Kitley J; Waters P; Woodhall M; Leite MI; Murchison A; George J; Küker W; Chandratre S; Vincent A; Palace J
JAMA Neurol; 2014 Mar; 71(3):276-83. PubMed ID: 24425068
[TBL] [Abstract][Full Text] [Related]
17. Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica.
Rostásy K; Mader S; Hennes EM; Schanda K; Gredler V; Guenther A; Blaschek A; Korenke C; Pritsch M; Pohl D; Maier O; Kuchukhidze G; Brunner-Krainz M; Berger T; Reindl M
Mult Scler; 2013 Jul; 19(8):1052-9. PubMed ID: 23257621
[TBL] [Abstract][Full Text] [Related]
18. Isolated new onset 'atypical' optic neuritis in the NMO clinic: serum antibodies, prognoses and diagnoses at follow-up.
Piccolo L; Woodhall M; Tackley G; Juryńczyk M; Kong Y; Domingos J; Gore R; Vincent A; Waters P; Leite MI; Palace J
J Neurol; 2016 Feb; 263(2):370-379. PubMed ID: 26668077
[TBL] [Abstract][Full Text] [Related]
19. Clinical and MRI phenotype of children with MOG antibodies.
Fernandez-Carbonell C; Vargas-Lowy D; Musallam A; Healy B; McLaughlin K; Wucherpfennig KW; Chitnis T
Mult Scler; 2016 Feb; 22(2):174-84. PubMed ID: 26041801
[TBL] [Abstract][Full Text] [Related]
20. [Anti-Myelin Oligodendrocyte Glycoprotein Antibodies in Paediatric Patients with Optic Neuritis].
Tegetmeyer H; Merkenschlager A
Klin Monbl Augenheilkd; 2017 Oct; 234(10):1243-1249. PubMed ID: 29025172
[No Abstract] [Full Text] [Related]
[Next] [New Search]